4-(4-fluoro-2-methoxyphenyl)-N-(3-(methylsulfonylmethyl)phenyl)-1,3,5-triazin-2-amine

ID: ALA4742789

PubChem CID: 66576206

Max Phase: Preclinical

Molecular Formula: C18H17FN4O3S

Molecular Weight: 388.42

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  COc1cc(F)ccc1-c1ncnc(Nc2cccc(CS(C)(=O)=O)c2)n1

Standard InChI:  InChI=1S/C18H17FN4O3S/c1-26-16-9-13(19)6-7-15(16)17-20-11-21-18(23-17)22-14-5-3-4-12(8-14)10-27(2,24)25/h3-9,11H,10H2,1-2H3,(H,20,21,22,23)

Standard InChI Key:  SIZCGYPBEMJYPU-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 29  0  0  0  0  0  0  0  0999 V2000
    3.7961   -8.3964    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.2128   -9.1131    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    4.6251   -8.3939    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.4950   -8.2797    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.4939   -9.1071    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2087   -9.5201    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.9252   -9.1066    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9223   -8.2761    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.2069   -7.8669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6368   -9.5173    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.6367  -10.3435    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3511  -10.7548    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0659  -10.3411    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0620   -9.5118    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3471   -9.1042    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.7790   -9.5190    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.3435   -8.2791    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.0562   -7.8636    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.7817  -10.7515    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    7.0648   -9.1060    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.0700   -8.2810    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3567   -7.8680    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6409   -8.2800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.6428   -9.1093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.3568   -9.5186    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9295   -9.5239    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5004   -9.5278    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  2  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  4  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 15  2  0
 15 10  1  0
  7 10  1  0
  5 16  1  0
 15 17  1  0
 17 18  1  0
 13 19  1  0
 16 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 20  1  0
 24 26  1  0
 26  2  1  0
  2 27  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4742789

   4-(4-Fluoro-2-methoxyphenyl)-N-{3-[(methylsulfonyl)methyl]phenyl}-1,3,5-triazin-2-amine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 388.42

Molecular Weight (Monoisotopic): 388.1005

AlogP: 2.97

#Rotatable Bonds: 6

Polar Surface Area: 94.07

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.44

CX Basic pKa: 2.42

CX LogP: 2.69

CX LogD: 2.69

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.69

Np Likeness Score: -1.60

References

1. Wu T,Qin Z,Tian Y,Wang J,Xu C,Li Z,Bian J.  (2020)  Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.,  63  (22): [PMID:32866383] [10.1021/acs.jmedchem.0c00744]

2. Mäder P,Kattner L.  (2020)  Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry.,  63  (23.0): [PMID:32870008] [10.1021/acs.jmedchem.0c00960]

3. Lücking U, Kosemund D, Böhnke N, Lienau P, Siemeister G, Denner K, Bohlmann R, Briem H, Terebesi I, Bömer U, Schäfer M, Ince S, Mumberg D, Scholz A, Izumi R, Hwang S, von Nussbaum F..  (2021)  Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.,  64  (15.0): [PMID:34264057] [10.1021/acs.jmedchem.1c01000]

4. Lücking U, Kosemund D, Böhnke N, Lienau P, Siemeister G, Denner K, Bohlmann R, Briem H, Terebesi I, Bömer U, Schäfer M, Ince S, Mumberg D, Scholz A, Izumi R, Hwang S, von Nussbaum F..  (2021)  Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.,  64  (15.0): [PMID:34264057] [10.1021/acs.jmedchem.1c01000]

Source

Source(1):

• Scientific Literature